CA2743433C - Anti-cmet antibody - Google Patents

Anti-cmet antibody Download PDF

Info

Publication number
CA2743433C
CA2743433C CA2743433A CA2743433A CA2743433C CA 2743433 C CA2743433 C CA 2743433C CA 2743433 A CA2743433 A CA 2743433A CA 2743433 A CA2743433 A CA 2743433A CA 2743433 C CA2743433 C CA 2743433C
Authority
CA
Canada
Prior art keywords
antibody
amino acid
seq
acid sequence
sequence seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2743433A
Other languages
English (en)
French (fr)
Other versions
CA2743433A1 (en
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2743433(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2743433A1 publication Critical patent/CA2743433A1/en
Application granted granted Critical
Publication of CA2743433C publication Critical patent/CA2743433C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
CA2743433A 2008-12-02 2009-12-02 Anti-cmet antibody Active CA2743433C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IBPCT/IB2008/055663 2008-12-02
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05
US61/184,502 2009-06-05
PCT/EP2009/066201 WO2010069765A1 (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Publications (2)

Publication Number Publication Date
CA2743433A1 CA2743433A1 (en) 2010-06-24
CA2743433C true CA2743433C (en) 2019-06-11

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2743433A Active CA2743433C (en) 2008-12-02 2009-12-02 Anti-cmet antibody

Country Status (38)

Country Link
US (4) US8741290B2 (enExample)
EP (4) EP2370468B1 (enExample)
JP (3) JP5863458B2 (enExample)
KR (1) KR101838299B1 (enExample)
CN (2) CN103351438B (enExample)
AR (1) AR074439A1 (enExample)
AU (3) AU2009328318C1 (enExample)
BR (2) BR122019023930B1 (enExample)
CA (1) CA2743433C (enExample)
CL (2) CL2011001296A1 (enExample)
CO (1) CO6382139A2 (enExample)
CR (1) CR20110324A (enExample)
CY (2) CY1119172T1 (enExample)
DK (2) DK3135691T3 (enExample)
EC (1) ECSP11011127A (enExample)
ES (3) ES2697098T3 (enExample)
GE (2) GEP20135930B (enExample)
HR (2) HRP20171011T8 (enExample)
HU (3) HUE051288T2 (enExample)
IL (2) IL213273A0 (enExample)
LT (2) LT2370468T (enExample)
MA (1) MA32892B1 (enExample)
MX (2) MX2011005677A (enExample)
MY (2) MY192567A (enExample)
NZ (1) NZ593853A (enExample)
PE (1) PE20120343A1 (enExample)
PH (1) PH12015501515A1 (enExample)
PL (3) PL3431502T3 (enExample)
PT (3) PT2370468T (enExample)
RS (2) RS56204B1 (enExample)
RU (2) RU2560257C2 (enExample)
SA (2) SA112331005B1 (enExample)
SG (2) SG171851A1 (enExample)
SI (3) SI3135691T1 (enExample)
TN (1) TN2011000216A1 (enExample)
TW (2) TWI523866B (enExample)
WO (1) WO2010069765A1 (enExample)
ZA (1) ZA201105164B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2992019B1 (en) 2013-04-30 2019-03-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
EP3411067B1 (en) * 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
TW201825515A (zh) * 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CN113164570B (zh) * 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020198731A2 (en) * 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
JP7510518B2 (ja) 2020-09-01 2024-07-03 レメゲン シーオー．，エルティーディー． 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4319811A1 (en) 2021-04-06 2024-02-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
AU2022254291A1 (en) * 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es) * 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
AU2024276234A1 (en) 2023-05-23 2025-12-04 AbbVie Manufacturing Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
CA2606102C (en) * 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
MX341014B (es) 2016-08-03
DK2370468T3 (en) 2017-06-19
US8747850B2 (en) 2014-06-10
ES2629855T3 (es) 2017-08-16
PT2370468T (pt) 2017-07-13
AU2017203929B2 (en) 2019-03-28
JP5863458B2 (ja) 2016-02-16
SA109300720B1 (ar) 2013-05-25
CN103351438A (zh) 2013-10-16
ES2827277T3 (es) 2021-05-20
SA112331005B1 (ar) 2015-09-13
EP3431502B1 (en) 2020-07-22
GEP20146207B (en) 2014-12-10
US20130109844A1 (en) 2013-05-02
JP2012510280A (ja) 2012-05-10
EP3431502A1 (en) 2019-01-23
CL2014000181A1 (es) 2014-07-25
AU2009328318C1 (en) 2017-11-02
MA32892B1 (fr) 2011-12-01
JP2017099392A (ja) 2017-06-08
LT3135691T (lt) 2018-11-12
CL2011001296A1 (es) 2011-08-26
GEP20135930B (en) 2013-10-10
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
PH12015501515A1 (en) 2015-12-14
TW201446805A (zh) 2014-12-16
TWI523866B (zh) 2016-03-01
HK1162536A1 (zh) 2012-08-31
MY185200A (en) 2021-04-30
AU2009328318A1 (en) 2011-07-28
JP6309657B2 (ja) 2018-04-11
KR20110097839A (ko) 2011-08-31
WO2010069765A1 (en) 2010-06-24
MX2011005677A (es) 2011-06-30
ECSP11011127A (es) 2011-07-29
US8729249B2 (en) 2014-05-20
US20130109841A1 (en) 2013-05-02
TWI459964B (zh) 2014-11-11
TW201023892A (en) 2010-07-01
LT2370468T (lt) 2017-07-10
KR101838299B1 (ko) 2018-03-14
HUE035047T2 (en) 2018-05-02
AU2016200725A1 (en) 2016-02-25
HUE051288T2 (hu) 2021-03-01
SG171851A1 (en) 2011-07-28
AR074439A1 (es) 2011-01-19
HK1190414A1 (zh) 2014-07-04
IL231525B (en) 2019-07-31
PL3135691T3 (pl) 2019-02-28
NZ593853A (en) 2013-03-28
HRP20181868T1 (hr) 2019-01-11
JP6074018B2 (ja) 2017-02-01
HRP20171011T1 (hr) 2017-09-22
SI3431502T1 (sl) 2021-01-29
PT3431502T (pt) 2020-10-29
SI2370468T1 (sl) 2017-08-31
DK3135691T3 (en) 2018-11-19
CA2743433A1 (en) 2010-06-24
RS56204B1 (sr) 2017-11-30
PL2370468T3 (pl) 2017-09-29
HUE040553T2 (hu) 2019-03-28
ZA201105164B (en) 2012-03-28
PL3431502T3 (pl) 2020-12-28
CN103351438B (zh) 2016-04-20
BRPI0923231B1 (pt) 2020-04-28
AU2017203929A1 (en) 2017-07-06
CO6382139A2 (es) 2012-02-15
US20110239316A1 (en) 2011-09-29
MY192567A (en) 2022-08-29
BRPI0923231B8 (pt) 2021-05-25
RU2011124751A (ru) 2013-01-10
RU2015127471A (ru) 2018-12-21
EP3135691A1 (en) 2017-03-01
ES2697098T3 (es) 2019-01-22
CY1121025T1 (el) 2019-12-11
IL231525A0 (en) 2014-04-30
US8765128B2 (en) 2014-07-01
US20130109840A1 (en) 2013-05-02
RU2560257C2 (ru) 2015-08-20
SI3135691T1 (sl) 2018-12-31
JP2016117721A (ja) 2016-06-30
EP3757132A1 (en) 2020-12-30
CR20110324A (es) 2011-07-28
CN102227446A (zh) 2011-10-26
CY1119172T1 (el) 2018-02-14
BR122019023930B1 (pt) 2021-05-04
AU2016200725B2 (en) 2017-05-25
CN102227446B (zh) 2015-10-21
AU2016200725C1 (en) 2017-10-19
SG187518A1 (en) 2013-02-28
EP2370468A1 (en) 2011-10-05
EP2370468B1 (en) 2017-04-05
RS58018B1 (sr) 2019-02-28
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
TN2011000216A1 (en) 2012-12-17
EP3135691B1 (en) 2018-08-15
BRPI0923231A2 (pt) 2016-01-26
PT3135691T (pt) 2018-11-27
AU2009328318B2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
AU2017203929B2 (en) ANTI-cMET ANTIBODY
CA2801264C (en) Novel anti-cmet antibody
US20230406940A1 (en) ANTI-cMET ANTIBODY
WO2010064089A1 (en) Novel anti-cmet antibody
US20140112911A9 (en) Novel anti-cmet antibody

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141104

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241121

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241121

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124